Abstract
Multiple myeloma (MM) accounts for around 1%-2% of all cancers, and it is more prevalent in men than women. MM is responsible for an estimated 176,000 cases and 117,000 deaths annually worldwide. Most myeloma malignancies contain genetic abnormalities that may be identified using sensitive molecular genetic methods such as interphase fluorescence in situ hybridization. The risk categorization has a high prognostic value and aids in the choice of initial treatment options. Diagnostic delays have been linked to worsening the disease's course and can lead to complications, including pathological fractures and renal failure. They are also connected with worse cancer stages and lower survival rates. There is a scarcity of published data in Saudi Arabia on the characteristics, management practices, as well as outcomes of MM patients. This review discusses the current trends and practices in MM worldwide and compares them with current Saudi Arabia practices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medicine in Developing Countries
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
